Biomimetic Nanoparticle Delivering Colchicine to Target Endothelial Inflammation for Atherosclerosis Treatment
Dysfunctional endothelium with chronic inflammation represents an early stage in the development of atherosclerotic plaques. Nanomedicines capable of targeting activated endothelium and resolving inflammation have great potential for atherosclerosis treatment. In this work, we developed biomimetic platelet membrane‐coated layered double hydroxide nanoparticles (PM‐LDH) for the targeted delivery of anti‐inflammatory drug colchicine to the inflamed endothelial cells and showed improved therapeutic effects by using the colchicine‐loaded PM‐LDH. Inspired by the natural interactions between platelets and activated endothelium, platelet membrane‐coated nanoparticles exhibited markedly high affinity for inflamed endothelial cells while reducing immune clearance by macrophages. The enhanced anti‐inflammatory efficacy was demonstrated by reduced monocyte recruitment and attenuated reactive oxygen species production in inflamed endothelial cells. Overall, through the platelet membrane–endothelium interaction, the biomimetic colchicine‐loaded nanoparticles show strong potential as a targeted therapeutic strategy for atherosclerosis.
Authors
- Ashish Misra (ORCID: https://orcid.org/0000-0002-3042-8302)
- Xiuwen Zhang (ORCID: https://orcid.org/0000-0003-1003-2885)
- Lingqing Zong
- Zi Gu (ORCID: https://orcid.org/0000-0002-7153-6596)
- Sanjay Patel
Institutions
- Royal Prince Alfred Hospital (AU)
- The Heart Research Institute (AU)
- UNSW Sydney (AU)
Publication Details
- Journal
- Advanced NanoBiomed Research
- Published
- 2026-05-23
- DOI
- https://doi.org/10.1002/anbr.202600004
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00